{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "8913444", "DateCompleted": {"Year": "1997", "Month": "03", "Day": "05"}, "DateRevised": {"Year": "2020", "Month": "07", "Day": "24"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0066-4804", "JournalIssue": {"Volume": "40", "Issue": "11", "PubDate": {"Year": "1996", "Month": "Nov"}}, "Title": "Antimicrobial agents and chemotherapy", "ISOAbbreviation": "Antimicrob Agents Chemother"}, "ArticleTitle": "In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis.", "Pagination": {"StartPage": "2447", "EndPage": "2451", "MedlinePgn": "2447-51"}, "Abstract": {"AbstractText": ["The antileishmanial efficacies of 2-n-propylquinoline, chimanines B and D, 2-n-pentylquinoline, 2-phenylquinoline, 2-(3,4-methylenedioxyphenylethyl) quinoline, and two total alkaloidal extracts of Galipea longiflora were evaluated in BALB/c mice infected with Leishmania amazonensis or Leishmania venezuelensis. Animals were treated for 4 to 6 weeks postinfection with a quinoline by the oral route at 50 mg/kg of body weight twice daily for 15 days or by five intralesional injections at intervals of 4 days with a quinoline at 50 mg/kg of body weight. The reference drug, N-methylglucamine antimonate (Glucantime), was administered by subcutaneous or intralesional injection (regimens of 14, 28, or 56 mg of pentavalent antimony [Sbv] per kg of body weight daily). Twice-daily oral treatment with chimanine B at 50 mg/kg resulted in a decrease in lesion weight by 70% (P < 0.001) and a decrease in the parasite loads by 95% (P < 0.001). Five injections of chimanine B at intervals of 4 days reduced the lesion weight by 74% and the parasite loads in the lesion by 90% compared with the values for the group of untreated mice. Subcutaneous administration of N-methylglucamine antimonate at 28 mg of Sbv kg per day for 15 days reduced the parasite burden by 95% (P < 0.001), and five intralesional injections at the same concentration reduced the parasite burden by 96% (P < 0.001). Other 2-substituted quinolines, 2-n-propylquinoline administered by the oral and intralesional routes, 2-phenylquinoline administered by the oral route, 2-n-pentylquinoline administered by intralesional injection, and two total alkaloidal extracts of G. longiflora administered by the oral route, had intermediate effects. These findings suggest that chimanine B may be chosen as a lead molecule in the development of oral therapy against leishmaniasis."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "ORSTOM, Institut Fran\u00e7ais de Recherche Scientifique pour le D\u00e9veloppement en Coop\u00e9ration, Asunci\u00f3n, Paraguay. fournet@ui131.una.py"}], "LastName": "Fournet", "ForeName": "A", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Ferreira", "ForeName": "M E", "Initials": "ME"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Rojas De Arias", "ForeName": "A", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Torres De Ortiz", "ForeName": "S", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Fuentes", "ForeName": "S", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Nakayama", "ForeName": "H", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Schinini", "ForeName": "A", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Hocquemiller", "ForeName": "R", "Initials": "R"}], "PublicationTypeList": ["Comparative Study", "Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Antimicrob Agents Chemother", "NlmUniqueID": "0315061", "ISSNLinking": "0066-4804"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "4-Quinolones"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Infective Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiprotozoal Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Organometallic Compounds"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "6HG8UB2MUY", "NameOfSubstance": "Meglumine"}, {"RegistryNumber": "75G4TW236W", "NameOfSubstance": "Meglumine Antimoniate"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "4-Quinolones"}, {"QualifierName": [], "DescriptorName": "Administration, Oral"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Anti-Infective Agents"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Antiprotozoal Agents"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Injections, Subcutaneous"}, {"QualifierName": ["drug therapy", "parasitology", "pathology"], "DescriptorName": "Leishmaniasis, Cutaneous"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Meglumine"}, {"QualifierName": [], "DescriptorName": "Meglumine Antimoniate"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Organometallic Compounds"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Antimicrob Agents Chemother. 1993 Apr;37(4):859-63", "ArticleIdList": ["8494383"]}, {"Citation": "Infect Immun. 1993 Jul;61(7):2952-9", "ArticleIdList": ["8514400"]}, {"Citation": "Parasitol Today. 1994 Feb;10(2):65-8", "ArticleIdList": ["15275504"]}, {"Citation": "Biotherapy. 1994;7(3-4):223-35", "ArticleIdList": ["7865353"]}, {"Citation": "AIDS. 1991 Feb;5(2):201-7", "ArticleIdList": ["2031693"]}, {"Citation": "Clin Investig. 1994 Dec;72(12):1041-7", "ArticleIdList": ["7711412"]}, {"Citation": "J Antimicrob Chemother. 1994 Mar;33(3):537-44", "ArticleIdList": ["8040117"]}, {"Citation": "Am J Trop Med Hyg. 1992 Jul;47(1):117-26", "ArticleIdList": ["1322070"]}, {"Citation": "Am J Pathol. 1995 Mar;146(3):635-42", "ArticleIdList": ["7887446"]}, {"Citation": "Clin Infect Dis. 1995 Jan;20(1):191", "ArticleIdList": ["7727652"]}, {"Citation": "Exp Parasitol. 1989 Jul;69(1):78-90", "ArticleIdList": ["2543590"]}, {"Citation": "Chem Pharm Bull (Tokyo). 1994 Sep;42(9):1914-6", "ArticleIdList": ["7954944"]}, {"Citation": "Infect Immun. 1983 Mar;39(3):1087-94", "ArticleIdList": ["6840835"]}, {"Citation": "Ann Intern Med. 1989 Jul 15;111(2):129-32", "ArticleIdList": ["2742248"]}, {"Citation": "Acta Trop. 1994 Feb;56(1):111-20", "ArticleIdList": ["7911268"]}, {"Citation": "Antimicrob Agents Chemother. 1995 Sep;39(9):2167-8", "ArticleIdList": ["8540741"]}], "ReferenceList": []}], "History": [{"Year": "1996", "Month": "11", "Day": "1"}, {"Year": "1996", "Month": "11", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1996", "Month": "11", "Day": "1", "Hour": "0", "Minute": "0"}, {"Year": "1996", "Month": "11", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["8913444", "PMC163555", "10.1128/AAC.40.11.2447"]}}]}